Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom

被引:20
作者
MacDonald, Thomas M. [1 ]
Morant, Steven V. [1 ,2 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Div Med & Therapeut, Dundee DD1 9SY, Scotland
[2] Cygnus Biostat Ltd, Haddenham, Scotland
关键词
cholesterol; cross-sectional studies; hypercholesterolaemia; hypertension; population-based prevalence; treatment patterns;
D O I
10.1111/j.1365-2125.2007.03072.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AIMS To determine the prevalence and treatment of hypertension, dyslipidaemia and both together in the UK between 1998 and 2006. METHODS We used The Health Improvement Network (THIN) a general practice-based database from 1998 to 2006 and we compared the 1998 and 2003 data to that taken from the Health Survey for England (HSE) in 1998 and 2003. RESULTS The prevalence (treatment) of hypertension was 25.3% (11.4%) in 1998, 27.8% (15.1%) in 2003 and 26.9% (16.2%) in 2006 in THIN. In HSE it was 37.3% (9.6%) in 1998 and 32.9% (13.8%) in 2003. For dyslipidaemia the figures were 8.6% (1.9%), 18.5% (6.5%) and 24.4% (9.8%) for THIN and 67.8% (2.3%) and 74.9% (7.0%) for HSE. Concurrent hypertension and dyslipidaemia in THIN increased from 5.5% (1.1%) in 1998 to 13.5% (4.5%) in 2003 and 17.4% (7.1%) in 2006. The prevalence of both conditions was 30.6% (0.7%) in HSE in 1998 and 28.7% (3.1%) in 2003. CONCLUSIONS There has been a progressive improvement in the detection and treatment of hypertension, dyslipidaemia and both conditions together between 1998 and 2006. However, much still needs to be done to improve the diagnosis and treatment of hypertension, hypercholesterolaemia and concurrent hypertension and hypercholesterolaemia in the United Kingdom.
引用
收藏
页码:775 / 786
页数:12
相关论文
共 52 条
[1]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[2]  
Bajekal M., 1999, HLTH SURVEY ENGLAND
[3]   PRIMARY NONCOMPLIANCE WITH PRESCRIBED MEDICATION IN PRIMARY-CARE [J].
BEARDON, PHG ;
MCGILCHRIST, MM ;
MCKENDRICK, AD ;
MCDEVITT, DG ;
MACDONALD, TM .
BRITISH MEDICAL JOURNAL, 1993, 307 (6908) :846-848
[4]  
Bourke Alison, 2004, Inform Prim Care, V12, P171
[5]   European guidelines on cardiovascular disease prevention in clinical practice -: Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice [J].
De Backer, G ;
Ambrosioni, E ;
Borch-Johnsen, K ;
Brotons, C ;
Cifkova, R ;
Dallongeville, J ;
Ebrahim, S ;
Faergeman, O ;
Graham, I ;
Mancia, G ;
Cats, VM ;
Orth-Gomér, K ;
Perk, J ;
Pyörälä, K ;
Rodicio, JL ;
Sans, S ;
Sansoy, V ;
Sechtem, U ;
Silber, S ;
Thomsen, T ;
Wood, D .
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2003, 10 (04) :S1-S10
[6]   Selected major risk factors and global and regional burden of disease [J].
Ezzati, M ;
Lopez, AD ;
Rodgers, A ;
Vander Hoorn, S ;
Murray, CJL .
LANCET, 2002, 360 (9343) :1347-1360
[7]   Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults - Findings from the National Health and Nutrition Examination Survey, 1999 to 2000 [J].
Ford, ES ;
Mokdad, AH ;
Giles, WH ;
Mensah, GA .
CIRCULATION, 2003, 107 (17) :2185-2189
[8]   From best evidence to best practice: effective implementation of change in patients' care [J].
Grol, R ;
Grimshaw, J .
LANCET, 2003, 362 (9391) :1225-1230
[9]   Therapeutic goal attainment in patients with hypertension and dyslipidemia [J].
Johnson, ML ;
Pietz, K ;
Battleman, DS ;
Beyth, RJ .
MEDICAL CARE, 2006, 44 (01) :39-46
[10]  
Johnson ML, 2004, AM J MANAG CARE, V10, P926